Trial Profile
A Multicenter, Randomized, Double-Blind, Phase 3 Study of Ramucirumab (IMC-1121B) Drug Product and Best Supportive Care (BSC) Versus Placebo and BSC as Second-Line Treatment in Patients With Hepatocellular Carcinoma Following First-Line Therapy With Sorafenib (REACH)
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 16 Jul 2022
Price :
$35
*
At a glance
- Drugs Ramucirumab (Primary)
- Indications Liver cancer
- Focus Registrational; Therapeutic Use
- Acronyms REACH
- Sponsors Eli Lilly and Company; ImClone Systems
- 07 Jun 2022 Results of pooled analysis of two studies (REACH & REACH-2) assessing efficacy and safety of ramucirumab in Chinese patients (including patients from mainland China, Hong Kong, and Taiwan), presented at the 58th Annual Meeting of the American Society of Clinical Oncology.
- 04 Mar 2022 Results assessing prognostic and predictive factors of response to ramucirumab in patients with aHCC with AFP {greater than or equal to}400 ng/mL from the Phase III REACH and REACH-2 randomized trials, published in the Clinical Cancer Research.
- 08 Jun 2021 Results assessing prognostic factors in patients with AFP ≥400 ng/mL and predictors of clinical benefit to ramucirumab in an individual participant data meta-analysis of the REACH and REACH-2 Phase III trials, presented at the 57th Annual Meeting of the American Society of Clinical Oncology.